BCRX vs PTCT

For growth investors, PTC Therapeutics, Inc.

(PTCT) is the stronger pick with 114. 5% revenue growth year-over-year, versus 94. 1% for BioCryst Pharmaceuticals, Inc. (BCRX). BioCryst Pharmaceuticals, Inc. (BCRX) offers the better valuation at 7. 4x trailing P/E (32. 9x forward), making it the more compelling value choice. Analysts rate BioCryst Pharmaceuticals, Inc. (BCRX) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, BioCryst Pharmaceuticals, Inc.

(BCRX) is the cheapest at 7. 4x versus PTC Therapeutics, Inc. at 8. 3x.

Over the past 5 years, PTC Therapeutics, Inc.

(PTCT) delivered a total return of +60. 3%, compared to -32. 2% for BioCryst Pharmaceuticals, Inc. (BCRX). Over 10 years, the gap is even starker: PTCT returned +733. 2% versus BCRX's +190. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioCryst Pharmaceuticals, Inc.

(BCRX) is the lower-risk stock at 0. 82β versus PTC Therapeutics, Inc. 's 1. 13β — meaning PTCT is approximately 38% more volatile than BCRX relative to the S&P 500.

By revenue growth (latest reported year), PTC Therapeutics, Inc.

(PTCT) is pulling ahead at 114. 5% versus 94. 1% for BioCryst Pharmaceuticals, Inc. (BCRX). On earnings-per-share growth, the picture is similar: BioCryst Pharmaceuticals, Inc. grew EPS 381. 4% year-over-year, compared to 264. 5% for PTC Therapeutics, Inc.. Over a 3-year CAGR, BCRX leads at 47. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

PTC Therapeutics, Inc.

(PTCT) is the more profitable company, earning 39. 4% net margin versus 30. 2% for BioCryst Pharmaceuticals, Inc. — meaning it keeps 39. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTCT leads at 49. 5% versus 39. 0% for BCRX. At the gross margin level — before operating expenses — BCRX leads at 97. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for BCRX: 91.

0% to $17. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, PTC Therapeutics, Inc.

(PTCT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 13), +733. 2% 10Y return). Both have compounded well over 10 years (PTCT: +733. 2%, BCRX: +190. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.